The Efficacy of Bisphosphonates in Preventing Aromatase Inhibitor Induced Bone Loss for Postmenopausal Women with Early Breast Cancer: A Systematic Review and Meta-Analysis
Table 5
Heterogeneity test results.
Outcome
value
Arthralgia
0.390
Bone pain
0.608
Back pain
0.744
Pain in extremity
0.056
Myalgia
0.794
LS BMD 12 months (normal at baseline-ZOL trials)
0.0003
LS BMD 12 months (osteopenic at baseline-ZOL trials)
0.296
LS BMD 12 months (residronate and ibandronate trials)
